Tsaturyan v. GlaxoSmithKline, LLC CA2/7
Sofik Tsaturyan, Sarkis Tatevosian, Manvel Hunanyan and Anna Guyumdzhyan each started taking Avandia, a drug manufactured by GlaxoSmithKline LLC (formerly SmithKline Beecham Corp.)(GSK) to help adults with type 2 diabetes control their blood sugar, between 2002 and 2007. Each of them was diagnosed with cardiovascular injury before or during 2007. In 2011 Tsaturyan, Tatevosian, Hunanyan and Guyumdzhyan sued GSK for failure to warn of Avandia’s alleged cardiovascular risks, asserting causes of action for negligence, strict liability and fraud. In January 2016 the trial court granted GSK’s motion for summary judgment, ruling the publicly available information regarding Avandia and any associated cardiovascular risks was sufficient to put Tsaturyan, Tatevosian, Hunanyan and Guyumdzhyan on notice of possible causes of action against GSK no later than December 31, 2007.
Comments on Tsaturyan v. GlaxoSmithKline, LLC CA2/7